NCT06054425View on ClinicalTrials.gov

A Study to Compare the Bioavailability of Intravenously Infused Risankizumab Manufactured by Two Different Processes in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

November 20, 2023

Primary Completion Date

May 6, 2024

Study Completion Date

May 6, 2024

Conditions
Healthy Volunteers
Interventions
DRUG

Risankizumab

Infusion; intravenous

Trial Locations (3)

33014

Clinical Pharmacology of Miami /ID# 260800, Miami

60030

Acpru /Id# 260864, Grayslake

92801-2658

Anaheim Clinical Trials LLC /ID# 260740, Anaheim

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
lead

AbbVie

INDUSTRY